hVIVO (LON:HVO) Receives “Add” Rating from Peel Hunt

hVIVO (LON:HVO)‘s stock had its “add” rating reaffirmed by analysts at Peel Hunt in a report released on Tuesday, Marketbeat reports. They currently have a GBX 21 ($0.28) price target on the stock. Peel Hunt’s price objective points to a potential upside of 100.00% from the company’s previous close.

Separately, Shore Capital reissued a “buy” rating and set a GBX 35 ($0.46) price objective on shares of hVIVO in a report on Tuesday, July 22nd.

hVIVO Stock Performance

Shares of LON HVO opened at GBX 10.50 ($0.14) on Tuesday. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm has a market cap of £74.30 million, a price-to-earnings ratio of 4.33 and a beta of 0.97. The business’s 50-day simple moving average is GBX 11.24 and its 200-day simple moving average is GBX 14.98. hVIVO has a 52 week low of GBX 6.50 ($0.09) and a 52 week high of GBX 30.45 ($0.40).

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.